Literature DB >> 28659246

Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.

Boshi Huang1, Xueshun Wang1, Xinhao Liu1, Zihui Chen1, Wanzhuo Li1, Songkai Sun1, Huiqing Liu2, Dirk Daelemans3, Erik De Clercq3, Christophe Pannecouque3, Peng Zhan4, Xinyong Liu5.   

Abstract

Crystallographic overlap studies and pharmacophoric analysis indicated that diarylpyrimidine (DAPY)-based HIV-1 NNRTIs showed a similar binding mode and pharmacophoric features as indolylarylsulfones (IASs), another class of potent NNRTIs. Thus, a novel series of DAPY-IAS hybrid derivatives were identified as newer NNRTIs using structure-based molecular hybridization. Some target compounds exhibited moderate activities against HIV-1 IIIB strain, among which the two most potent inhibitors possessed EC50 values of 1.48μM and 1.61μM, respectively. They were much potent than the reference drug ddI (EC50=76.0μM) and comparable to 3TC (EC50=2.54μM). Compound 7a also exhibited the favorable selectivity index (SI=80). Preliminary structure-activity relationships (SARs), structure-cytotoxicity relationships, molecular modeling studies, and in silico calculation of physicochemical properties of these new inhibitors were also discussed.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Crystallographic overlays; DAPY-IAS hybrids; Drug design; HIV-1 inhibitors; Molecular modeling; SARs

Mesh:

Substances:

Year:  2017        PMID: 28659246     DOI: 10.1016/j.bmc.2017.06.022

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  1 in total

1.  Isoquinoline Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-like 2 (KEAP1-NRF2) Inhibitors with High Metabolic Stability.

Authors:  Phillip R Lazzara; Brian P David; Aparna Ankireddy; Benjamin G Richardson; Katherine Dye; Kiira M Ratia; Sekhar P Reddy; Terry W Moore
Journal:  J Med Chem       Date:  2019-11-14       Impact factor: 7.446

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.